Skip to Main Content
Table 5.

Joint effects of the MTHFR C677T polymorphism and HRT use at baseline on breast cancer risk

Duration (y)CC
CT
TT
n*OR (95% CI)nOR (95% CI)nOR (95% CI)
HRT use       
    Never 240/619 1.00 170/418 0.95 (0.74-1.21) 63/137 1.01 (0.71-1.43) 
    1-3 146/325 1.07 (0.83-1.38) 143/262 1.14 (0.87-1.48) 32/65 0.96 (0.60-1.53) 
    >3 129/180 1.35 (1.01-1.79) 121/147 1.48 (1.10-1.99) 31/53 0.94 (0.58-1.54) 
    P 0.35      
Duration (y)CC
CT
TT
n*OR (95% CI)nOR (95% CI)nOR (95% CI)
HRT use       
    Never 240/619 1.00 170/418 0.95 (0.74-1.21) 63/137 1.01 (0.71-1.43) 
    1-3 146/325 1.07 (0.83-1.38) 143/262 1.14 (0.87-1.48) 32/65 0.96 (0.60-1.53) 
    >3 129/180 1.35 (1.01-1.79) 121/147 1.48 (1.10-1.99) 31/53 0.94 (0.58-1.54) 
    P 0.35      
*

No. cases/no. controls (in comparison with Table 4, an additional 14 cases and 40 controls were excluded due to missing information on HRT duration).

ORs (95% CIs) adjusted for ethnicity and age at blood draw.

P value derived from a likelihood ratio test comparing a model with main effects for the MTHFR C677T genotype and the HRT use (Never, 1-3 years of use, >3 years of use), and a model with main effects and interaction terms (df, 4).

Close Modal

or Create an Account

Close Modal
Close Modal